Inhibition of Insulin-induced Activation of Akt by a Kinase-deficient Mutant of the epsilon  Isozyme of Protein Kinase C*

Michihiro MatsumotoDagger , Wataru OgawaDagger §, Yasuhisa HinoDagger , Kensuke FurukawaDagger , Yoshitaka Ono, Mikiko Takahashi, Motoi Ohba, Toshio Kuroki, and Masato KasugaDagger

From the Dagger  Second Department of Internal Medicine, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, the  Biosignal Research Center, and the Graduate School of Science and Technology, Kobe University, Kobe 657-8501, Institute of Molecular Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Received for publication, December 11, 2000




    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Akt, also known as protein kinase B, is a protein-serine/threonine kinase that is activated by growth factors in a phosphoinositide (PI) 3-kinase-dependent manner. Although Akt mediates a variety of biological activities, the mechanisms by which its activity is regulated remain unclear. The potential role of the epsilon  isozyme of protein kinase C (PKC) in the activation of Akt induced by insulin has now been examined. Expression of a kinase-deficient mutant of PKCepsilon (epsilon KD), but not that of wild-type PKCepsilon or of kinase-deficient mutants of PKCalpha or PKClambda , with the use of adenovirus-mediated gene transfer inhibited the phosphorylation and activation of Akt induced by insulin in Chinese hamster ovary cells or L6 myotubes. Whereas the epsilon KD mutant did not affect insulin stimulation of PI 3-kinase activity, the phosphorylation and activation of Akt induced by a constitutively active mutant of PI 3-kinase were inhibited by epsilon KD, suggesting that epsilon KD affects insulin signaling downstream of PI 3-kinase. PDK1 (3'-phosphoinositide-dependent kinase 1) is thought to participate in Akt activation. Overexpression of PDK1 with the use of an adenovirus vector induced the phosphorylation and activation of Akt; epsilon KD inhibited, whereas wild-type PKCepsilon had no effect on, these actions of PDK1. These results suggest that epsilon KD inhibits the insulin-induced phosphorylation and activation of Akt by interfering with the ability of PDK1 to phosphorylate Akt.




    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Akt, also known as protein kinase B, is activated by growth factors such as platelet-derived growth factor (PDGF)1 and insulin (1-3), by cytokines (4), by ligands of G protein-coupled receptors (5), and by cellular stresses such as hyperosmolarity, heat shock, fluid shear stress, and hydrogen peroxide-induced oxidative stress (6-8). The activation of Akt by these stimuli contributes to a variety of their biological effects, including promotion of cell survival and protection from apoptosis (4, 9), induction of meiosis in oocytes (10), regulation of vascular contractility (8, 11), activation of the transcription factor NF-kappa B (12, 13), and various metabolic actions of insulin (14-17).

Activation of Akt is mediated by phosphorylation of a threonine residue in the kinase activation loop (Thr308 in Akt1) and a serine residue in the COOH-terminal region (Ser473 in Akt1) (18). Akt mutants in which these residues are replaced by neutral amino acids are not activated in cells (15, 18). The phosphorylation and activation of Akt induced by growth factors are blocked by pharmacological or molecular biological inhibitors of phosphoinositide (PI) 3-kinase (1-3, 15), indicating that PI 3-kinase is required for the phosphorylation of Thr308 and Ser473 and activation of Akt in response to growth factors.

PDK1 (3'-phosphoinositide-dependent kinase 1), originally identified as a kinase that selectively phosphorylates Thr308 of Akt in vitro, is thought to contribute to Akt activation (19-21). However, the mechanism by which PDK1 phosphorylates Akt in intact cells remains unclear. Although the phosphorylation of Akt by PDK1 is stimulated in the presence of 3'-phosphoinositides in vitro (19-21), the kinase activity of PDK1 immunoprecipitated from cells is not affected by prior treatment of the cells with either growth factors or pharmacological inhibitors of PI 3-kinase (22), suggesting that PDK1 is constitutively active in cells. Given that Akt translocates from the cytosol to the membrane fraction of cells in response to growth factors (23), and that membrane-targeted mutants of Akt are constitutively active in quiescent cells (23, 24), it is thought that membrane-associated Akt is phosphorylated by PDK1.

Mutational analysis has revealed that phosphorylation of both Thr308 and Ser473 is required for Akt activation (18). Although a kinase that phosphorylates Ser473 of Akt has been tentatively designated PDK2, its nature remains unclear. Balendran et al. (25) recently showed that PDK1 phosphorylates Ser473 of Akt in vitro only in the presence of a glutathione S-transferase (GST) fusion protein that contains the COOH-terminal portion of protein kinase C (PKC)-related kinase 2 (PRK2) or of synthetic peptides corresponding to this region of PRK2. In contrast, the phosphorylation of p70 S6 kinase by PDK1 was inhibited in the presence of the same GST fusion protein or peptides (26). Moreover, when overexpressed in intact cells, this same region of PRK2 prevented ligand-induced activation of p70 S6 kinase (26). These observations suggest that the interactions of PDK1 with its substrates, at least those with Akt and p70 S6 kinase, are regulated by another kinase.

PKCepsilon is a member of the novel subfamily of PKC isozymes (27, 28). When expressed in fibroblasts also expressing various mutant PDGF receptors, PKCepsilon contributed to the transactivation of the TPA (12-O-tetradecanoylphorbol 13-acetate)-responsive element induced by PDGF in a PI 3-kinase-dependent manner (29), suggesting that PKCepsilon participates in signaling downstream of PI 3-kinase. We have therefore now investigated whether PKCepsilon plays a role in activation of Akt. We examined the effects of overexpression of wild-type or a kinase-deficient mutant of PKCepsilon on Akt activation induced by insulin, heat shock, or hydrogen peroxide. Expression of the kinase-deficient mutant of PKCepsilon inhibited the phosphorylation and activation of Akt in response to all three stimuli, probably by affecting the ability of PDK1 to phosphorylate Akt.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Antibodies-- L6 myoblasts were maintained and induced to differentiate into myotubes as described previously (30). We amplified a full-length mouse serum- and glucocorticoid-regulated protein kinase (SGK) 2 cDNA (31) by the polymerase chain reaction (PCR) with cDNA synthesized from RNA extracted from mouse liver as template. The amplified SGK2 cDNA was tagged with the HA epitope at its NH2 terminus with the use of PCR. To establish CHO-IR cells that express (in addition to insulin receptors) FLAG epitope-tagged Akt1 or HA epitope-tagged SGK2 (CHO-IR/Akt cells and CHO-IR/SGK2 cells, respectively), we transfected CHO-IR cells with pSV40-hgh (which confers resistance to hygromycin) and a PECE vector encoding FLAG-tagged rat Akt1 (RAC-PKalpha ) (6) or a pCMV4 vector encoding HA-tagged mouse SGK2. Transfected cells were selected and cloned as described previously (32). CHO-IR cells that express phosphodiesterase 3B (PDE3B), designated CHO-IR/PDE3B-WT cells, were previously described (16). Polyclonal antibodies to Akt, to mitogen-activated protein (MAP) kinase, and to PDE3B were generated as described previously (15, 16, 33). Polyclonal antibodies to PKCepsilon as well as monoclonal antibodies to PKCalpha and to PKClambda were obtained from Santa Cruz Biotechnology and Transduction Laboratories, respectively. Monoclonal antibodies to the HA epitope tag (12CA5) or to the FLAG epitope tag were obtained from Roche Molecular Biochemicals. Polyclonal antibodies specific for phospho-Thr308 or phospho-Ser473 forms of Akt or for the phosphorylated form of MAP kinase were obtained from New England BioLabs.

Construction of and Infection with Adenovirus Vectors-- Adenovirus vectors encoding a kinase-deficient mutant of PKClambda in which Lys273 is replaced by glutamate (AxCAlambda KD) (32), or a constitutively active mutant of PI 3-kinase (AxCAMyr-p110) (16, 34) were described previously. Complementary DNAs for wild-type PKCepsilon (epsilon WT, Ref. 27) and a kinase-deficient mutant of PKCepsilon in which Lys437 is replaced by methionine (epsilon KD, Ref. 35) were modified with the use of PCR to encode the T7 or FLAG epitope tags at the NH2 termini of the respective proteins. A kinase-deficient mutant of PKCepsilon in which Thr566 is replaced by alanine (epsilon T566A) was as described (36). A constitutively active mutant of PKCepsilon in which Ala159 is replaced by glutamate (epsilon A159E) was constructed from the cDNA that encodes FLAG epitope-tagged epsilon WT with the use of a QuickChange site-directed mutagenesis kit (Stratagene). Complementary DNAs encoding T7-tagged epsilon WT, the FLAG-tagged epsilon KD, epsilon T566A, FLAG-tagged epsilon A159E, Myc epitope-tagged PDK1 (21), kindly provided by L. Stephens (The Babraham Institute), or a kinase-deficient mutant of PKCalpha in which Lys368 is replaced with arginine (37) were subcloned into pAxCAwt (38), and adenoviral vectors containing these cDNAs were generated with the use of an adenovirus expression kit (Takara, Tokyo, Japan) as described previously (15, 16). The resultant adenovirus vectors were termed AxCAepsilon WT, AxCAepsilon KD, AxCAepsilon T566A, AxCAepsilon A159E, AxCAPDK1, and AxCAalpha KD, respectively. CHO-IR/Akt cells or differentiated L6 myotubes were infected with adenovirus vectors at the indicated multiplicity of infection (MOI), expressed in plaque-forming units (PFU) per cell, as described previously (33). The cells were subjected to experiments 24-48 h after infection.

Kinase Assays-- L6 myotubes or CHO-IR/Akt cells were deprived of serum for 16-20 h, incubated in the absence or presence of 100 nM insulin for the indicated time, and then immediately frozen with liquid nitrogen. The assay for MAP kinase activity was performed with immunoprecipitates prepared with antibodies to MAP kinase, as described previously (33). For assay of PI 3-kinase activity, cells were lysed and subjected to immunoprecipitation with antibodies to phosphotyrosine (PY20; Transduction Laboratories); the resulting immunoprecipitates were washed and PI 3-kinase activity in the washed precipitates was assayed as described previously (33). For assay of Akt activity, cells were lysed and subjected to immunoprecipitation with polyclonal antibodies to Akt as described (15). The immunoprecipitates were then mixed with 30 µl of kinase reaction mixture containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 1 mM of the specific peptide inhibitor of cAMP-dependent protein kinase (PKI), 5 µM nonradioactive ATP, 2 µCi of [gamma -32P]ATP (4000 Ci/mmol), and 5 µM Crosstide peptide (GRPRTSSFAEG) (39) and then incubated for 30 min at 30 °C. Assay of SGK activity was performed essentially as described (40) with the following modifications. Cells were lysed in a solution containing 50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1% Triton X-100, 1 mM benzamidine, 25 mM NaF, 40 mM beta -glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, and leupeptin (10 µg/ml). The lysate was centrifuged, and the resulting supernatant was subjected to immunoprecipitation with antibodies to HA. The immunoprecipitates were washed once with the lysis buffer containing 500 mM NaCl and with the lysis buffer and then twice with 50 mM Tris-HCl, pH 7.5 containing 0.1% (v/v) of beta -mercaptoethanol. The immunoprecipitates were then mixed with 30 µl of kinase reaction mixture containing 60 mM Tris-HCl, pH 7.5, 12 mM MgCl2, 0.12 mM EDTA, 0.12% (v/v) beta -mercaptoethanol, 3 µg/ml of PKI, 5 µM nonradioactive ATP, 4 µCi of [gamma -32P]ATP (4000 Ci/mmol), and 36 µM Crosstide peptide, and then incubated for 60 min at 30 °C. The kinase recation mixture for Akt or SGK was spotted onto a P81 phosphocellulose filter (Whatman), the filters were washed three times with 0.5% (w/v) orthophosphoric acid, and the radioactivity remaining on the filters was measured.

In Vivo Phosphorylation of PDE3B-- The in vivo phosphorylation of PDE3B was assayed as described previously (16). In brief, CHO-IR/PDE3B-WT cells, previously infected (or not) with AxCAepsilon KD, were labeled with [32P]orthophosphate, incubated in the absence or presence of 100 nM insulin for 15 min, and lysed. Cell lysates were subjected to immunoprecipitation with polyclonal antibodies to PDE3B, the resulting precipitates were separated by SDS-polyacrylamide gel electrophoresis on a 7% gel, and the incorporation of radioactivity into PDE3B was visualized and quantitated with a Fuji BAS2000 image analyzer.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effects of Wild-type and a Kinase-deficient Mutant of PKCepsilon on Insulin-induced Activation of Akt-- Infection of CHO-IR/Akt cells, which stably express both human insulin receptors and rat Akt1, with an adenovirus vector that encodes a kinase-deficient mutant of PKCepsilon (AxCAepsilon KD) resulted in a dose-dependent increase in the amount of PKCepsilon protein as assessed by immunoblot analysis; the amount of PKCepsilon protein in cells infected at an MOI of 10 PFU/cell was ~10-20 times that of endogenous PKCepsilon (Fig. 1A). Exposure of noninfected CHO-IR/Akt cells to insulin resulted in a >30-fold increase in the amount of Akt activity measured in immunoprecipitates prepared with antibodies to Akt (Fig. 1A). Expression of the kinase-deficient mutant of PKCepsilon (epsilon KD) in the cells inhibited insulin-induced activation of Akt in a dose-dependent manner. Infection of CHO-IR/Akt cells with AxCAepsilon KD also inhibited insulin-induced phosphorylation of both Thr308 and Ser473 of Akt, as assessed by immunoblot analysis with antibodies specific for either phospho-Thr308 or phospho-Ser473 forms of Akt (Fig. 1A). Expression of a structurally distinct kinase deficient mutant of PKCepsilon (epsilon T566A) also exerted similar inhibitory effects on insulin-induced activity (Fig. 1B) and phosphorylation (data not shown) of Akt in CHO-IR/Akt cells.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of wild-type and kinase-deficient mutants of PKCepsilon on insulin-induced phosphorylation and activation of Akt. CHO-IR/Akt cells (A and B) or L6 mytotubes (C and D) that had been infected with either AxCAepsilon KD (A and C), AxCAepsilon T566A (B) or AxCAepsilon WT (D) at the indicated MOI (PFU/cell) were incubated in the absence or presence of 100 nM insulin for 10 min and then lysed. The cell lysates were either subjected to immunoprecipitation with antibodies to Akt and thereby assayed for Akt activity (upper panels), or subjected to immunoblot analysis with antibodies to PKCepsilon , to the phospho-Thr308 (pT308), or the phospho-Ser473 (pS473) forms of Akt, or to total Akt (lower panels). Quantitative data are means ± S.E. from three experiments. Immunoblot data are representative of three independent experiments.

We next investigated whether epsilon KD exerted a similar inhibitory effect on Akt activation in physiological target cells of insulin. Insulin induced an approximately 6-fold increase in Akt activity in L6 myotubes (Fig. 1C). Expression of epsilon KD inhibited insulin-induced phosphorylation and activation of Akt in a dose-dependent manner (Fig. 1C). In contrast, overexpression of wild-type PKCepsilon in L6 myotubes did not affect insulin-induced phosphorylation and activation of Akt (Fig. 1D). Expression of wild-type PKCepsilon also had no effect on the activation of Akt in response to insulin in CHO-IR/Akt cells, and expression of either wild-type PKCepsilon or a constitutively active mutant of PKCepsilon (epsilon A159E), of which kinase activity was ~10-fold higher than that of wild-type PKCepsilon (data not shown), inconsistent with a previous report (41), did not induce Akt activation in the absence of insulin in CHO/IR Akt cells or in L6 myotubes (data not shown). These results suggest that epsilon KD inhibits insulin-induced activation of Akt by preventing the phosphorylation of Thr308 and Ser473, and that signal mediated through PKCepsilon alone is not sufficient to activate Akt in both CHO-IR/Akt cells and L6 myotubes.

Effects of Kinase-deficient Mutants of Various PKC Isozymes on Insulin-induced Activation of Akt-- We investigated whether kinase-deficient mutants of other PKC isozymes also affected the activation of Akt by insulin. Infection of L6 myotubes with adenovirus vectors encoding epsilon KD, wild-type PKCepsilon , or kinase-deficient mutants of PKCalpha (alpha KD) or PKClambda (lambda KD) resulted in marked expression of the encoded proteins (Fig. 2A); at an MOI of 20 PFU/cell; the amount of each recombinant protein was at least 10 times that of the corresponding endogenous PKC isoform. Whereas expression of epsilon KD inhibited insulin-induced activation of Akt, alpha KD had no effect on this action of insulin (Fig. 2A). The expression of lambda KD resulted in a slight enhancement of the effect of insulin on Akt activity, consistent with previous observations (42).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of kinase-deficient mutants of various PKC isozymes on insulin-induced activation of Akt (A) and effects of epsilon KD on Akt activation induced by heat shock or hydrogen peroxide (B). A, L6 mytotubes that had been infected (or not) with either AxCAepsilon KD (epsilon KD), AxCAepsilon WT (epsilon WT), AxCAalpha KD (alpha KD), or AxCAlambda KD (lambda KD) at an MOI of 20 PFU/cell were incubated in the absence or presence of 100 nM insulin for 10 min and then lysed. Cell lysates were either subjected to immunoprecipitation with antibodies to Akt and thereby assayed for Akt activity (upper panel), or subjected to immunoblot analysis with antibodies to PKCepsilon , to PKCalpha , or to PKClambda (lower panel). B, CHO-IR/Akt cells that had been infected (or not) with AxCAepsilon KD at an MOI of 10 PFU/cell were either incubated for 10 min in the absence or presence of 8.8 mM hydrogen peroxide or subjected to heat shock for 10 min at 45 °C. Cell lysates were then prepared and either subjected to immunoprecipitation with antibodies to Akt and thereby assayed for Akt activity (upper panel), or subjected to immunoblot analysis with antibodies to PKCepsilon or to phospho-Thr308 or to phospho-Ser473 forms of Akt. Quantitative data are means ± S.E. from three experiments. Immunoblot data are representative of three independent experiments.

Effects of a Kinase-deficient Mutant of PKCepsilon on Akt Activation Induced by Heat Shock or Hydrogen Peroxide-- Akt is also activated by heat shock and by hydrogen peroxide (6, 7). These stimuli induced ~10- and 20-fold increases in Akt activity, respectively, in CHO-IR/Akt cells (Fig. 2B). Expression of epsilon KD inhibited the activation of Akt in response to either heat shock or hydrogen peroxide. The phosphorylation of Akt on Thr308 and Ser473 induced by these stimuli was also inhibited by expression of epsilon KD (Fig. 2B).

Effect of a Kinase-deficient Mutant of PKCepsilon on Insulin-induced Phosphorylation of PDE3B-- PDE3B was recently identified as a direct substrate of Akt (16). In CHO-IR cells expressing PDE3B, insulin induced an approximately 2-fold increase in the extent of phosphorylation of PDE3B (Fig. 3). Infection of the cells with AxCAepsilon KD at an MOI of 3 PFU/cell, a virus dose that inhibited insulin-induced activation of Akt by ~50% in CHO-IR/Akt cells (Fig. 1A), resulted in ~50% inhibition of insulin-induced phosphorylation of PDE3B. This observation suggests that inhibition by epsilon KD of Akt activation attenuates signaling downstream of Akt.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of epsilon KD on insulin-induced phosphorylation of PDE3B. CHO-IR/PDE3B-WT cells that had been infected (or not) with AxCAepsilon KD at an MOI of 3 PFU/cell were labeled with [32P]orthophosphate, incubated in the absence or presence of 100 nM insulin for 15 min, and lysed. Cell lysates were subjected to immunoprecipitation with antibodies to PDE3B, the resulting precipitates were subjected to electrophoresis, and 32P incorporation into PDE3B was visualized (lower panel) or quantitated (upper panel) with an image analyzer. Quantitative data are means of two experiments, and the image shown is representative of two independent experiments.

Effect of a Kinase-deficient Mutant of PKCepsilon on Signaling Downstream of PI 3-Kinase-- We further attempted to identify the step of the insulin signaling pathway leading to activation of Akt that is affected by epsilon KD. Overexpression of epsilon KD had no effect on the insulin-induced increase in the activity of PI 3-kinase immunoprecipitated from L6 myotubes with antibodies to phosphotyrosine (Fig. 4A), suggesting that epsilon KD affects insulin-induced activation of Akt at a step downstream of PI 3-kinase. To verify this conclusion, we examined the effect of epsilon KD on the activation of Akt by a constitutively active mutant of PI 3-kinase, Myr-p110, which comprises the catalytic subunit of PI 3-kinase ligated to a myristoylation signal sequence at its NH2 terminus (16, 34). Infection of L6 myotubes with an adenovirus vector encoding Myr-p110 (AxCAMyr-p110) induced both the phosphorylation and activation of Akt (Fig. 4B). Coexpression of epsilon KD inhibited in a dose-dependent manner the phosphorylation and activation of Akt induced by Myr-p110 (Fig. 4B); expression of epsilon KD did not affect the amount Myr-p110 protein as assessed by immunoblot analysis (data not shown). These observations are thus consistent with the notion that epsilon KD inhibits insulin-induced activation of Akt by affecting signaling downstream of PI 3-kinase. Expression of epsilon KD did not affect insulin-induced phosphorylation and activation of MAP kinase (Fig. 4C), indicating that early events of insulin signaling, such as activation of the insulin receptor kinase and phosphorylation of its substrates, are not prevented by epsilon KD.



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of epsilon KD on insulin-induced activation of PI 3-kinase (A) and MAP kinase (C) as well as on Akt activation by Myr-p110 (B). A and C, L6 mytotubes that had been infected with AxCAepsilon KD at the indicated MOI (PFU/cell) were incubated in the absence or presence of 100 nM insulin for 10 min and then lysed. The lysates were subjected to immunoprecipitation with antibodies to phoshotyrosine (A) or to MAP kinase (C), and the resulting precipitates were assayed for PI 3-kinase and MAP kinase activities, respectively. Alternatively, cell lysates from (C) were subjected to immunoblot analysis with antibodies to phospho-MAP kinase or to total MAP kinase (MAPK, lower panel). B, L6 mytotubes were infected (or not) with AxCAMyr-p110 at an MOI of 10 PFU/cell and, after 12 h, with AxCAepsilon KD at the indicated MOI (PFU/cell). After an additional 36 h, the cells were lysed and the lysates were either subjected to immunoprecipitation with antibodies to Akt and thereby assayed for Akt activity (upper panel) or subjected to immunoblot analysis with antibodies to PKCepsilon , to the phospho-Ser473 form of Akt, or to total Akt (lower panel). Quantitative data are means ± S.E. from three experiments. Immunoblot data are representative of three independent experiments.

Effect of a Kinase-deficient Mutant of PKCepsilon on PDK1-induced Activation of Akt-- PDK1 is a serine/threonine kinase that phosphorylates and activates Akt in vitro (19-21). We thus investigated the effect of epsilon KD on PDK1-induced activation of Akt. Infection of CHO-IR/Akt cells with an adenovirus vector encoding PDK1 (AxCAPDK1) induced the phosphorylation of Akt on both Thr308 and Ser473 as well as the activation of this enzyme (Fig. 5). Coexpression of epsilon KD with PDK1 resulted in inhibition of the PDK1-induced phosphorylation and activation of Akt, with no effect on the amount of PDK1 protein. In contrast, expression of wild-type PKCepsilon had no effect on the phosphorylation and activation of Akt induced by PDK1. These results suggest that epsilon KD inhibited the ability of PDK1 to phosphorylate and activate Akt.



View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of epsilon KD on PDK1-induced phosphorylation and activation of Akt. CHO-IR/Akt cells were infected (or not) with AxCAPDK1 at an MOI of 10 PFU/cell and, after 12 h, with either AxCAepsilon KD or AxCAepsilon WT also at an MOI of 10 PFU/cell. After an additional 36 h, the cells were lysed and the lysates were either subjected to immunoprecipitation with antibodies to Akt and thereby assayed for Akt activity (upper panel), or subjected to immunoblot analysis with antibodies to PKCepsilon , to the phospho-Thr308 or the phospho-Ser473 forms of Akt, or to Myc (for PDK1) (lower panel). Quantitative data are means ± S.E. from three experiments. Immunoblot data are representative of three independent experiments.

Effect of a Kinase-deficient Mutant of PKCepsilon on Insulin-induced Activation of SGK-- PDK1 has recently been shown to contribute to the phosphorylation and the activation of SGK (31, 40, 43). We finally investigated the effect of epsilon KD on insulin-induced activation of SGK. CHO-IR/SGK2 cells, which stably express both human insulin receptors and HA-tagged mouse SGK2, were incubated in the absence or presence of insulin for 10 min, lysed, and immunoprecipitated with antibodies to HA, and then SGK kinase activity toward Crosstide was assayed in the immunoprecipitates. Insulin induced ~6-fold increase in the activity of SGK, and overexpression of epsilon KD in the cells inhibited insulin-induced activation of SGK in a dose-dependent manner (Fig. 6).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of epsilon KD on insulin-induced activation of SGK. CHO-IR/SGK2 cells that had been infected (or not) with AxCAepsilon KD at the indicated MOI (PFU/cell) were incubated in the absence or presence of 100 nM insulin for 10 min and then lysed. The cell lysates were subjected to immunoprecipitation with antibodies to HA and assayed for SGK activity. Data are means ± S.E. from three experiments.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have shown that overexpression of kinase-deficient mutants of PKCepsilon (epsilon KD or epsilon T566A) with the use of adenovirus-mediated gene transfer inhibited the phosphorylation and activation of Akt induced by insulin. An adenovirus vector encoding wild-type PKCepsilon had no effect on the insulin-induced increase in Akt activity, and the virus encoding epsilon KD had no effect on insulin-induced activation of either MAP kinase or PI 3-kinase, suggesting that the inhibition of Akt activation by epsilon KD is due neither to nonspecific effects of viral infection nor to general inhibition of insulin signaling. The phosphorylation and activation of Akt induced by heat shock or hydrogen peroxide were also inhibited by epsilon KD, suggesting that this mutant protein affects a common component of the Akt activation pathways triggered by various extracellular stimuli. PI 3-kinase acts as an upstream mediator of Akt activation induced by several stimuli (1-3, 5, 7). However, our observations that epsilon KD both did not inhibit insulin-induced activation of PI 3-kinase and prevented Akt activation by a constitutively active mutant of PI 3-kinase indicate that epsilon KD affects a signaling component that acts downstream of PI 3-kinase.

PDK1 was originally identified as a kinase that phosphorylates Thr308 of Akt in vitro (20, 21), and an unidentified kinase that phosphorylates Ser473 of Akt has been termed PDK2. We have now shown that overexpression of PDK1 induced the phosphorylation of Akt on both Thr308 and Ser473 in intact cells. PDK1 has been shown to phosphorylate Ser473 of Akt in vitro in the presence of a GST fusion protein containing the COOH-terminal region of PRK2 or of synthetic peptides that encompass this region of PRK2 (25). It is thus possible that, in intact cells, PDK1 phosphorylates both Thr308 and Ser473 of Akt, which would explain why overexpression of PDK1 alone resulted in the activation of Akt. We cannot, however, exclude the possibility that expression of PDK1 resulted in the activation of PDK2, and that PDK1 and PDK2 coordinately phosphorylate and activate Akt.

We have shown that epsilon KD inhibited PDK1-induced phosphorylation and activation of Akt, suggesting that epsilon KD affects the insulin signaling pathway at a step downstream of PDK1 action. PDK1 has been shown, at least in vitro, to phosphorylate not only Akt but various other kinases including p70 S6 kinase (44), SGK (31, 40, 43), p90RSK (45), cAMP-dependent protein kinase (46), and PKC isozymes including PKCzeta and PKCdelta (47), all of which belong to the AGC family of protein kinases. Thus, the observation that epsilon KD inhibited insulin-induced activity of SGK is also consistent with this hypothesis that epsilon KD interfere with the insulin signaling at a step downstream of PDK1. Given that PKCepsilon is a member of this family of kinases, it also might serve as a substrate for PDK1. However, it is not likely that epsilon KD inhibits insulin-induced activation of Akt simply by competing with Akt for PDK1, because expression of wild-type PKCepsilon did not inhibit this effect of insulin.

The mechanism by which epsilon KD inhibits the ability of PDK1 to activate Akt remains unclear. It is possible that endogenous PKCepsilon phosphorylates an unidentified substrate that is important for the interaction between PDK1 and Akt, and that epsilon KD exerts a dominant-negative effect on endogenous PKCepsilon . Our observation that overexpression of wild-type PKCepsilon or a constitutively active form of PKCepsilon alone did not increase Akt activity in the absence of insulin may be explained if such a substrate is constitutively phosphorylated in cells, so that overexpression of the wild-type or a constitutively active enzyme would not alter the phosphorylation state of the substrate.

The COOH-terminal region of PRK2, which includes a consensus sequence for a PDK2 phosphorylation site similar to that present in Akt with the exception that the residue equivalent to Ser473 is aspartic acid, modulates PDK1 activity (25, 26). Analysis of the three-dimensional structure of PDK1 suggests the presence in the kinase domain of a hydrophobic pocket that interacts with this region of PRK2 (48). Given that PKCepsilon also contains a sequence similar to the COOH-terminal region of PRK2, it is possible that epsilon KD affects the ability of PDK1 to phosphorylate Akt by interacting with the hydrophobic pocket of PDK1. Whereas serine and threonine residues in the COOH-terminal region of wild-type PKCbeta II are phosphorylated in intact cells, those of a kinase-deficient mutant of the enzyme are not (49). It is thus possible that the phosphorylation status of wild-type PKCepsilon and epsilon KD differ and that the difference in the abilities of these molecules to affect Akt activation might be because of such a difference in phosphorylation status.


    FOOTNOTES

* This work was supported by a grant-in-aid for the Research for the Future Program from the Japan Society for the Promotion of Science (to M. K.), grants from the Ministry of Education, Science, Sports, and Culture of Japan (to M. K. and W. O.), Health Sciences Research grants (Research on Human Genome and Gene Therapy) from the Ministry of Health and Welfare (to M. K.), and grants from Novartis Science Foundation and Yamanouchi Foundation for Research on Metabolic Disorders (to W. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 81-78-382-5861; Fax: 81-78-382-2080; E-mail: ogawa@med.kobe-u.ac.jp.

Published, JBC Papers in Press, January 22, 2001, DOI 10.1074/jbc.M011093200


    ABBREVIATIONS

The abbreviations used are: PDGF, platelet-derived growth factor; PI, phosphoinositide; PDK, 3'-phosphoinositide-dependent kinase; GST, glutathione S-transferase; PKC, protein kinase C; PRK2, PKC-related kinase 2; SGK, serum- and glucocorticoid-regulated protein kinase; PCR, polymerase chain reaction; PDE3B, phosphodiesterase 3B; MAP, mitogen-activated protein; MOI, multiplicity of infection; PFU, plaque-forming unit; CHO, Chinese hamster ovary; WT, wild-type.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Burgering, B. M. T., and Coffer, P. J. (1995) Nature 376, 599-602[CrossRef][Medline] [Order article via Infotrieve]
2. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazluskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. (1995) Cell 81, 727-736[Medline] [Order article via Infotrieve]
3. Kohn, A. D., Kovacina, K. S., and Roth, R. A. (1995) EMBO J. 14, 4288-4295[Abstract]
4. de Peso, L., Gonzalez-Galcia, M., Page, C., Herrera, R., and Nunez, G. (1997) Science 278, 687-689[Abstract/Free Full Text]
5. Murga, C., Laguinge, L., Wetzker, R., Cuadrado, A. M., and Gutkind, J. S. (1998) J. Biol. Chem. 273, 19080-19085[Abstract/Free Full Text]
6. Konishi, H., Matsuzaki, H., Tanaka, M., Ono, Y., Tokunaga, C., Kuroda, S., and Kikkawa, U. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7639-7643[Abstract/Free Full Text]
7. Morag, S., Cohen, P., and Alessi, D. R. (1998) Biochem. J. 336, 241-246[Medline] [Order article via Infotrieve]
8. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., and Zeiher, A. M. (1999) Nature 399, 601-605[CrossRef][Medline] [Order article via Infotrieve]
9. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-667[Abstract/Free Full Text]
10. Andersen, C. B., Roth, R. A., and Conti, M. (1998) J. Biol. Chem. 273, 18705-18708[Abstract/Free Full Text]
11. Fulton, D., Gratton, J. P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., and Sessa, W. C. (1999) Nature 399, 597-601[CrossRef][Medline] [Order article via Infotrieve]
12. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) Nature 401, 82-85[CrossRef][Medline] [Order article via Infotrieve]
13. Romashkova, J. A., and Makarov, S. S. (1999) Nature 401, 86-90[CrossRef][Medline] [Order article via Infotrieve]
14. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem. 271, 31372-31378[Abstract/Free Full Text]
15. Kitamura, T., Ogawa, W., Sakaue, H., Hino, Y., Kuroda, S., Takata, M., Matsumoto, M., Maeda, T., Konishi, H., Kikkawa, U., and Kasuga, M. (1998) Mol. Cell. Biol. 18, 3708-3717[Abstract/Free Full Text]
16. Kitamura, T., Kitamura, Y., Kuroda, S., Hino, Y., Ando, M., Kotani, K., Konishi, H., Matsuzaki, H., Kikkawa, U., Ogawa, W., and Kasuga, M. (1999) Mol. Cell. Biol. 19, 6286-6296[Abstract/Free Full Text]
17. Takata, M., Ogawa, W., Kitamura, T., Hino, Y., Kuroda, S., Kotani, K., Klip, A., Gingras, A.-C., Sonenberg, N., and Kasuga, M. (1999) J. Biol. Chem. 274, 20611-20618[Abstract/Free Full Text]
18. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B. A. (1996) EMBO J. 15, 6541-6551[Abstract]
19. Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., Ashworth, A., and Bownes, M. (1997) Curr. Biol. 7, 776-789[Medline] [Order article via Infotrieve]
20. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269[Medline] [Order article via Infotrieve]
21. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R., Reese, C. B., McCormick, F., Tempst, P., Coadwell, J., and Hawkins, P. T. (1998) Science 279, 710-714[Abstract/Free Full Text]
22. Dong, L. Q., Zhang, R.-B., Langlais, P., He, H., Matthew, C., Zhu, L., and Liu, F. (1999) J. Biol. Chem. 274, 8117-8122[Abstract/Free Full Text]
23. Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 31515-31524[Abstract/Free Full Text]
24. Kohn, A. D., Takeuchi, F., and Roth, R. A. (1996) J. Biol. Chem. 271, 21920-21926[Abstract/Free Full Text]
25. Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P., and Alessi, D. R. (1999) Curr. Biol. 9, 393-404[CrossRef][Medline] [Order article via Infotrieve]
26. Balendran, A., Currie, R., Armstrong, C. G., Avruch, J., and Alessi, D. R. (1999) J. Biol. Chem. 274, 37400-37406[Abstract/Free Full Text]
27. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K., and Nishizuka, Y. (1988) J. Biol. Chem. 263, 6927-6932[Abstract/Free Full Text]
28. Mellor, H., and Parker, P. J. (1998) Biochem. J. 332, 281-292[Medline] [Order article via Infotrieve]
29. Moriya, S., Kazlauskas, A., Akimoto, K., Hirai, S., Mizuno, K., Takenawa, T., Fukui, Y., Watanabe, Y., Ozaki, S., and Ohno, S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 151-155[Abstract/Free Full Text]
30. Mitsumoto, Y., Liu, Z., and Klip, A. (1993) Endocrine J. 1, 307-315
31. Kobayashi, T., Deak, M., Morrice, N., and Cohen, P. (1999) Biochem. J. 344, 189-197[CrossRef][Medline] [Order article via Infotrieve]
32. Kotani, K., Ogawa, W., Matsumoto, M., Kitamura, T., Sakaue, H., Hino, Y., Miyake, K., Sano, W., Akimoto, K., Ohno, S., and Kasuga, M. (1998) Mol. Cell. Biol. 18, 6971-6982[Abstract/Free Full Text]
33. Sakaue, H., Ogawa, W., Takata, M., Kuroda, S., Kotani, K., Matsumoto, M., Sakaue, M., Nishio, S., Ueno, H., and Kasuga, M. (1997) Mol. Endocrinol. 11, 1552-1562[Abstract/Free Full Text]
34. Kotani, K., Ogawa, W., Hino, Y., Kitamura, T., Ueno, H., Sano, W., Sutherland, C., Granner, D. K., and Kasuga, M. (1999) J. Biol. Chem. 274, 21305-21312[Abstract/Free Full Text]
35. Kuroda, S., Tokunaga, C., Kiyohara, Y., Higuchi, O., Konishi, H., Mizuno, K., and Kikkawa, U. (1996) J. Biol. Chem. 271, 31029-31032[Abstract/Free Full Text]
36. Takahashi, M., Mukai, H., Oishi, K., Isagawa, T., and Ono, Y. (2000) J. Biol. Chem. 275, 34592-34596[Abstract/Free Full Text]
37. Ohno, S., Konno, Y., Akita, Y., Yano, Y., and Suzuki, K. (1990) J. Biol. Chem. 265, 6296-6300[Abstract/Free Full Text]
38. Miyake, S., Makimura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1320-1324[Abstract/Free Full Text]
39. Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
40. Kobayashi, T., and Cohen, P. (1999) Biochem. J. 339, 319-328[CrossRef][Medline] [Order article via Infotrieve]
41. Genot, E. M., Parker, P. J., and Cantrell, D. A. (1995) J. Biol. Chem. 270, 9833-9839[Abstract/Free Full Text]
42. Doornbos, R. P., Theelen, M., van der Hoeven, P. C., van Blitterswijk, W. J., Verkleij, A. J., and van Bergen en Henegouwen, P. M. (1999) J. Biol. Chem. 274, 8589-8596[Abstract/Free Full Text]
43. Park, J., Leong, M. L., Buse, P., Maiyar, A. C., Firestone, G. L., and Hemmings, B. A. (1999) EMBO J. 18, 3024-3033[Abstract/Free Full Text]
44. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B., and Thomas, G. (1998) Science 279, 707-710[Abstract/Free Full Text]
45. Jensen, C. J., Buch, M. B., Krag, T. O., Hemmings, B. A., Gammeltoft, S., and Frodin, M. (1999) J. Biol. Chem. 274, 27168-27176[Abstract/Free Full Text]
46. Cheng, X., Ma, Y., Moore, M., Hemmings, B. A., and Taylor, S. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9848-9854
47. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045[Abstract/Free Full Text]
48. Biondi, R. M., Cheung, P. C., Casamayor, A., Deak, M., Currie, R. A., and Alessi, D. R. (2000) EMBO J. 19, 979-988[Abstract/Free Full Text]
49. Behn-Krappa, A., and Newton, A. C. (1999) Curr. Biol. 9, 728-737[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.